Botanicure explained the company from different dimensions, including the dual-engine business strategy, scarcity of Alzheimer's disease drugs in the market, changes in US FDA regulations, Botanicure's foundation and competitive advantages, Botanicure's functional board of directors, and Botanicure's investment prospects.
Vice Chairman of Lesheng Yang Wenta looks at Botanicure's investment potential from an international financial perspective
Chien-Chun Li looks at Botanicure's opportunities from FDA regulatory changes and biotech stock issues
Through this briefing, potential investors and old shareholders of Botanicure finally understood the major phased changes that Botanicure will achieve in 2024:
♦︎ Functional Board of Directors Strategic Layout
(International Marketing/International Finance/US Regulations/Biotechnology Research and Development/Production Management)
♦︎Botanicure is a uniquely differentiated biotech stock
(Ant Hero Investment Strategy)
(Dual engine strategy, R&D and performance are both correct)
(Biotech stock with the highest proportion of foreign investment)
♦︎ In response to changes in US FDA regulations
(Forming a national team for biotech R&D, ushering in a new dawn of new plant drugs)
(IRB and multi-stage unblinding create opportunities for Botanicure's stock market to rise)